Minireviews
Copyright ©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1111-1119
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1111
Table 1 Conditions and drugs contributing to fatigue burden[1,2]
Conditions
Drugs
Addison disease; Anaemia; Autonomic dysfunction; Cancer; Chronic Lyme disease; Dehydration; Depression; Diabetes; Heart failure; Hypothyroidism; Infectious/inflammatory state; Myasthenia gravis; Multiple sclerosis; Obstructive sleep apnoea; Parkinson’s disease; Pregnancy; Renal failure; Restless legs syndrome; TuberculosisAntibiotics; Antidepressants; Anti-hypertensive therapy; Muscle relaxants; Opioids; Sedative-hypnotics
Table 2 Failed therapeutic options and future therapeutic perspectives for fatigue in primary biliary cholangitis
Treatment for fatigue in PBC
Ref.
Failed therapeutic options
Ursodeoxycholic acidAngulo et al[32], 1999
Obeticholic acidHirschfield et al[33], 2015
BudesonideHirschfield et al[37], 2021
FluoxetineTalwalkar et al[18], 2006
Fluvoxamineter Borg et al[19], 2004
OndansetronTheal et al[20], 2005
RituximabKhanna et al[14], 2019
ModafinilSilveira et al[16], 2017
MethotrexateCombes et al[48], 2005
Oral antioxidant supplementationPrince et al[23], 2003
Lifestyle changes
Morning bright light treatmentTurco et al[15], 2018
Home-based exercise programmeFreer et al[46], 2021
Possible future therapeutic options
FibratesCorpechot et al[35], 2018
PlasmapheresisWunsch et al[40], 2021
S-adenosyl-L-methionineWunsch et al[45], 2018
SeladelparKremer et al[44], 2022